Linking Social Cohesion to Biological Markers of Aging: Evidence From the National Health and Aging Trends Study.

Social cohesion, a measure of community belonging, and inflammatory biomarkers, like interleukin-6 (IL-6) and c-reactive protein (CRP), have emerged as significant factors influencing age-related chronic conditions and functional decline among older adults. Understanding the link between social cohesion and inflammation is particularly relevant in aging populations, as with age, social networks often diminish, and the prevalence of inflammatory conditions increases. Using data from the National Health and Aging Trends Study (NHATS), we assessed the relationship between low social cohesion and IL-6 and CRP.

Colour Preference of Post Hatchling Hawksbill () and Green () Sea Turtles in Captivity.

Variations in the ecological roles of sea turtle species may lead to differentiations in ocular design and visual sensitivity to the colour spectrum. Behavioural colour preference studies in air and in water on hatchling and post-hatchling green turtles found evidence of a blue hue attractiveness when given a choice between blue, red, and yellow. This paper assessed and compared the colour preferences to singular colours via the behavioural responses of eleven hawksbill turtles and twelve green turtles at 15 months of age and at 22 months of age.

Sexual Violence and Assault in Rural Australia: A Scoping Review of Regional, Rural, and Remote Contexts.

Sexual violence (SV) is an insidious social phenomenon that results in physical, emotional, and psychological trauma. The aim of this article is to review the research pertaining to SV in regional, rural, and remote Australia. A systematic scoping review was undertaken using the Arksey and O'Malley five-step framework.

Highlights from the breakout session: optimising new treatments.

This session presented emerging realworld evidence on novel glucocorticoid (GC) sparing therapies for ANCA-associated vasculitis (AAV). It covered the first-in-class oral C5a receptor antagonist avacopan for severe granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), and antiinterleukin-5 therapies in the management of eosinophilic granulomatosis with polyangiitis (EGPA). Avacopan was approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of AAV in 2021, following the phase 3 ADVOCAT E trial comparing oral avacopan to an oral GC taper for GPA and MPA.